Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

First Posted Date
2017-11-21
Last Posted Date
2022-10-20
Lead Sponsor
Julio Barredo, MD
Target Recruit Count
6
Registration Number
NCT03349281
Locations
🇺🇸

University of Miami, Miami, Florida, United States

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

First Posted Date
2017-09-18
Last Posted Date
2022-09-28
Lead Sponsor
National Hospital Organization Nagoya Medical Center
Target Recruit Count
60
Registration Number
NCT03286634
Locations
🇯🇵

Kagoshima University Hospital, Kagoshima, Japan

🇲🇾

University of Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Subang Jaya, Malaysia

and more 7 locations

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

First Posted Date
2017-09-14
Last Posted Date
2021-04-29
Lead Sponsor
Celgene
Target Recruit Count
35
Registration Number
NCT03283202
Locations
🇪🇸

Hospital Universitario Virgen Del Rocio, Sevilla, Spain

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

and more 12 locations

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

First Posted Date
2017-09-07
Last Posted Date
2024-10-04
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03274492
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Southern Cancer Center, Daphne, Alabama, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 240 locations

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

First Posted Date
2017-07-26
Last Posted Date
2018-06-28
Lead Sponsor
Assiut University
Target Recruit Count
40
Registration Number
NCT03229746
Locations
🇪🇬

Assiut university hospital, Assiut, Egypt

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

First Posted Date
2017-07-21
Last Posted Date
2020-09-02
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
25
Registration Number
NCT03225924
Locations
🇧🇪

UCL Namur, Yvoir, Belgium

🇧🇪

Institut Jules Bordet, Bruxelles, Belgium

🇧🇪

Az Groeninge, Kortrijk, Belgium

and more 24 locations

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

First Posted Date
2017-07-02
Last Posted Date
2023-12-11
Lead Sponsor
University Hospital Muenster
Target Recruit Count
650
Registration Number
NCT03206671
Locations
🇫🇮

Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland

🇨🇭

Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland

🇨🇭

Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-05-10
Last Posted Date
2024-03-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03147612
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2017-04-18
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
790
Registration Number
NCT03117751
Locations
🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

🇺🇸

St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States

🇦🇺

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

First Posted Date
2017-01-18
Last Posted Date
2017-01-18
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
174
Registration Number
NCT03023358
Locations
🇨🇳

Ru Feng, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy